HIFU, which stands for high intensity focused ultrasound is a recently approved new technology for prostate tissue ablation. Many urologists have worked with HIFU for several years to offer their patients a minimally invasive treatment option for prostate cancer, either as a part of a clinical trial or at international treatment centers outside the United States. There are currently two different medical devices that use HIFU energy to heat and destroy tissue in the prostate. The most technologically advanced HIFU device for prostate cancer is called the Sonablate. The Sonablate is a software directed device that includes a computer console, a transrectal probe and a chilling unit. The Sonablate software that physicians use to plan and execute Sonablate HIFU treatment has state-of-the-art features that make [...]
John McLean brings significant amount of experience in HIFU, operations, marketing and medical imaging. CHARLOTTE, N.C. March 9, 2016. HIFU Prostate Services, LLC, a leading provider of minimally invasive prostate cancer treatments using high intensity focused ultrasound (“HIFU”), is pleased to announce the addition of John McLean as chief operating officer. McLean brings 17 years of experience in healthcare marketing and management to HIFU Prostate Services and will be responsible for managing treatment teams, training programs and marketing initiatives. Prior to joining HIFU Prostate Services, McLean spent eight years at SonaCare Medical where he was involved in approximately 600 HIFU cases. While at SonaCare Medical, McLean served as product manager, business manager and service engineer; he brings experience in all areas of running a successful [...]
It has been very exciting to be able to offer HIFU to men with prostate cancer the past 6 years. The utility of the procedure continues to grow, with the evolution from merely whole gland therapy to the possibility of focal therapy. With MRI imaging improvements, we can not only limit treatment to the cancer focus in appropriate men, we can now better determine which patients are likely to have successful outcomes with whole gland therapy. Tissue Change Monitoring (TCM) has inspired me to modify the treatment on whole glands to lessen the risk of complications. It is impressive that many of my patients have done the math and found HIFU to be a relative bargain due their ability to go right back to work. [...]
Patients diagnosed with prostate cancer are faced with treatment options. The historical remedies—radiation therapy, surgery, hormonal therapy, chemotherapy and freezing the cancerous gland—have risks and negative side effects, especially incontinence and impotence. A new technology, however, is coming of age in its ability to diminish these risks and side effects. This nonsurgical outpatient option—high intensity focused ultrasound (HIFU)—takes approximately one to four hours to perform, depending on prostate size, and has a relatively short recovery period. With HIFU, most patients are up and walking around within two to three hours and may resume normal activities within a couple of days, with minimal discomfort.1 HIFU patients also experience fewer side effects than those receiving traditional prostate treatments.2 During the first two weeks after the procedure, patients [...]
When Dr. Michael Lazar makes weekend trips to Puerto Vallarta, Mexico, it's for business — to use a high-tech device to treat men with prostate cancer. Lazar, a Santa Rosa urologist for 30 years, is the only Northern California physician regularly treating patients with high-intensity focused ultrasound, known as HIFU, which is currently not approved for use in the United States. But HIFU, used for a decade or more in other countries, is "hands-down," Lazar said, the best treatment for prostate cancer, the most non-skin common cancer in men and second only to lung cancer in deaths. HIFU is the only non-invasive and radiation-free treatment for the disease, which was diagnosed in nearly 240,000 American men last year and caused almost 30,000 deaths, Lazar said. [...]
by Michael J. Lazar, MD Prostate cancer is the leading form of solid organ cancer in the U.S. and the fourth most common form of cancer in the world. According to the U.S. National Institutes of Health, the U.S. had more than 27,000 deaths in 2009 due to prostate cancer, which usually strikes older men. Those who have been diagnosed with prostate cancer and have explored treatment options have been faced with some difficult choices. Which treatment is likely to be most effective? Which has the fewest associated risks? What are the side effects? Traditional treatments include: radiation therapy, surgery, freezing the cancerous gland, hormonal therapy and chemotherapy. Physicians base treatment recommendations on many factors such as tumor size, spread of the disease and the [...]
Reported in AUA Daily Scope, from The Telegraph (British magazine): Combination chemotherapy and immune therapy resulted in enhanced immune system activation against widespread human prostate cancer that had been implanted in mice. The metastatic disease was “wiped out”. This is exciting, but it remains to be seen whether similar results will be seen in humans. Over the years, many promising animal model therapies have not translated into useful treatments in people. For all our similarities to animals, we are much more complex, and their corresponding immune systems may be stronger than ours through natural selection over time.